Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
IMPORTANCE: The emergency of COVID-19 requires the implementation of urgent strategies to
prevent the spread of the disease, mainly in health personnel, who are the most exposed and
has the highest risk of becoming infected with the SARS-COV-2.
OBJECTIVE: To evaluate the protective effect of the combination Ivermectin - Iota-
Carrageenan, intensive treatment with repeated administration in oral- and nasal-spray,
respectively, as a prophylaxis treatment prior to exposure to SARS-CoV-2, in health personnel
at Public Healthcare Centers.
PARTICIPANTS, DESIGN AND SETTING: Randomized controlled 1-1 clinical trial in Personal
Health, n = 234. The subjects were divided into experimental (EG)and control groups (CG). The
EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6
sprays per day for 4 weeks. All participants were evaluated by physical examination COVID-19
diagnosed with negative RT-PCR at the beginning, final, and follow-up of the protocol.
Differences between the variables were determined using the Chi-square test. The proportion
test almost contagious subject and the contagion risk (Odd Ratio) were calculated using
software STATA. The level of statistical significance was reached when p-Value < 0.05.